Spotlight on Hematology

Credits: 0.50 CME
Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Vindico

Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Hematology Presentations

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Treating High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Expert Perspectives on Treating High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize recommendations for molecular and cytogenic testing of patients with AML and how these results can be used to inform treatment decisions.
  2. Formulate informed treatment plans for patients with high-risk or relapsed/refractory AML, taking into consideration the latest clinical evidence regarding the safety and efficacy of recently approved therapies.
  3. Assess late-phase clinical trial data on investigational therapies and novel combination approaches within the context of existing AML treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

High-risk and relapsed/refractory AML represent significant clinical challenges. Within the past several years, eight novel agents have been approved for the treatment of AML, providing hope for improved outcomes in the coming years. With the wide variety of agents under development for the treatment of high-risk and relapsed/refractory AML, the use of recently approved and investigational agents is anticipated to continue to expand over the next few years. To continue to provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the utility of agents that could significantly impact clinical practice.

Faculty

Eytan M. Stein, MD
Director, Program for Drug Development in Leukemia
Assistant Professor
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Stein has consulted for:
Syndax, Syros, Novartis, Astellas, Daiichi, Gilead, Abbvie, Genentech, Janssen, BMS, Celgene, Agios, Blueprint, Neoleukin, PinotBio

Dr. Stein has research grants from:
Bayer, Syndax, Novartis, Biotheryx, Gilead, Agios

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie Inc., Agios Pharmaceuticals, Inc., and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize recommendations for molecular and cytogenic testing of patients with AML and how these results can be used to inform treatment decisions.
  2. Formulate informed treatment plans for patients with high-risk or relapsed/refractory AML, taking into consideration the latest clinical evidence regarding the safety and efficacy of recently approved therapies.
  3. Assess late-phase clinical trial data on investigational therapies and novel combination approaches within the context of existing AML treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

High-risk and relapsed/refractory AML represent significant clinical challenges. Within the past several years, eight novel agents have been approved for the treatment of AML, providing hope for improved outcomes in the coming years. With the wide variety of agents under development for the treatment of high-risk and relapsed/refractory AML, the use of recently approved and investigational agents is anticipated to continue to expand over the next few years. To continue to provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the utility of agents that could significantly impact clinical practice.

Faculty

Eytan M. Stein, MD
Director, Program for Drug Development in Leukemia
Assistant Professor
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Stein has consulted for:
Syndax, Syros, Novartis, Astellas, Daiichi, Gilead, Abbvie, Genentech, Janssen, BMS, Celgene, Agios, Blueprint, Neoleukin, PinotBio

Dr. Stein has research grants from:
Bayer, Syndax, Novartis, Biotheryx, Gilead, Agios

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie Inc., Agios Pharmaceuticals, Inc., and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Clinical Strategies to Optimize Outcomes Across the Disease Spectrum in Multiple Myeloma

Clinical Strategies to Optimize Outcomes Across the Disease Spectrum in Multiple Myeloma

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: March 9, 2021
Expires: March 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  1. Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
  2. Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
  3. Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.

The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.

Faculty

Jeffrey V. Matous, MD
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO


Conflict of Interest Policy/Disclosure Statement

Research Grant: Pharmacyclics
Consultant: Pharmacyclics

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: March 9, 2021
Expires: March 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  1. Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
  2. Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
  3. Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.

The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.

Faculty

Jeffrey V. Matous, MD
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO


Conflict of Interest Policy/Disclosure Statement

Research Grant: Pharmacyclics
Consultant: Pharmacyclics

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.50 CME
Vindico
Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge

Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications - A Game On! Challenge

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: March 2, 2021
Expires: March 1, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent cytomegalovirus (CMV) disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement of survival in transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of the virus is categorized into prophylactic, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicity, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Faculty

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Chief Infection Control Officer
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure:
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 2, 2021 to March 1, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.50 CME
Integrity Continuing Education, Inc.
Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML

Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML

Start

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: February 25, 2021
Expires: February 25, 2022
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

  • Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
  • Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
  • Describe case scenarios in which maintenance therapy may become standard in the near future
  • Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas


Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: February 25, 2021
Expires: February 25, 2022
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

  • Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
  • Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
  • Describe case scenarios in which maintenance therapy may become standard in the near future
  • Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas


Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.

0.25 CME
University of Nebraska Medical Center
Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma CME

Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma CME

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 1, 2021
Expires: February 1, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
  • Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
  • Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
  • Discuss clinical trials results that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Pieter Sonneveld, MD, PhD
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen, Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen, Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics

Chair European Myeloma Network
Chair Hovon Myeloma Working Group

Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 1, 2021
Expires: February 1, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
  • Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
  • Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
  • Discuss clinical trials results that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Pieter Sonneveld, MD, PhD
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen, Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen, Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics

Chair European Myeloma Network
Chair Hovon Myeloma Working Group

Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.

Contact Information for Questions About the Activity

info@bioascend.com

0.50 CME
University of Nebraska Medical Center
Podium to Practice: Recent Clinical Trial Updates of Current and Emerging Approaches for the Treatment of Relapsed/Refractory Multiple Myeloma

Podium to Practice: Recent Clinical Trial Updates of Current and Emerging Approaches for the Treatment of Relapsed/Refractory Multiple Myeloma

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 28, 2021
Expires: January 28, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review currently available treatment options for patients with R/R MM, and the unmet need for novel approaches, agents, and combinations in this setting
  • Evaluate the efficacy and safety of recently published clinical trial data of emerging agents and strategies being investigated in patients with R/R MM
  • Assess strategies to incorporate novel therapies into practice as they become available

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia


Nina Shah, MD
Associate Professor
Department of Medicine
University of California, San Francisco
San Francisco, California


Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Nina Shah, MD
Disclosures
Consulting Fees: bluebird bio, Inc., Celgene Corporation, Janssen Oncology, Sutro Biopharma, Inc., TeneoBio
Contracted Research & Publishing: Amgen Inc., Bristol Myers Squibb, CareDx, Genentech, Inc., GlaxoSmithKline LLC, Indapta Therapeutics, Nektar Therapeutics, Precision BioSciences, Sanofi, Surface Oncology
Ownership Interest:
Indapta Therapeutics

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from Karyopharm Therapeutics, Legend Biotech, and Sanofi Genzyme.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 28, 2021
Expires: January 28, 2022
30 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Review currently available treatment options for patients with R/R MM, and the unmet need for novel approaches, agents, and combinations in this setting
  • Evaluate the efficacy and safety of recently published clinical trial data of emerging agents and strategies being investigated in patients with R/R MM
  • Assess strategies to incorporate novel therapies into practice as they become available

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia


Nina Shah, MD
Associate Professor
Department of Medicine
University of California, San Francisco
San Francisco, California


Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Nina Shah, MD
Disclosures
Consulting Fees: bluebird bio, Inc., Celgene Corporation, Janssen Oncology, Sutro Biopharma, Inc., TeneoBio
Contracted Research & Publishing: Amgen Inc., Bristol Myers Squibb, CareDx, Genentech, Inc., GlaxoSmithKline LLC, Indapta Therapeutics, Nektar Therapeutics, Precision BioSciences, Sanofi, Surface Oncology
Ownership Interest:
Indapta Therapeutics

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from Karyopharm Therapeutics, Legend Biotech, and Sanofi Genzyme.

Contact Information for Questions About the Activity

info@bioascend.com

1.00 CME
University of Nebraska Medical Center
Multiple Myeloma Practicums: Caring for Patients in an Ever-Changing Treatment Environment

Multiple Myeloma Practicums: Caring for Patients in an Ever-Changing Treatment Environment

Start

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: December 14, 2020
Expires: December 14, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate various frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Discuss maintenance therapy options that may be appropriate for patients with MM
  • Assess strategies for proper sequencing of agents and regimens in patients with progressive disease
  • Review common adverse events that are associated with various treatment strategies and approaches to mitigating such adverse events

Activity Description

This activity will provide expert guidance regarding the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents. It is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.

Statement of Educational Need

Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

All disclosed conflicts of interest have been resolved by independent content review.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen, and Oncopeptides.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: December 14, 2020
Expires: December 14, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate various frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Discuss maintenance therapy options that may be appropriate for patients with MM
  • Assess strategies for proper sequencing of agents and regimens in patients with progressive disease
  • Review common adverse events that are associated with various treatment strategies and approaches to mitigating such adverse events

Activity Description

This activity will provide expert guidance regarding the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents. It is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs.

Statement of Educational Need

Major advances in the diagnosis and treatment of MM have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. As we go forward with these strategies, clinicians treating patients with MM need expert guidance to evaluate best practices and emerging clinical data and plan strategies to apply them safely and effectively to their patients.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

All disclosed conflicts of interest have been resolved by independent content review.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen, and Oncopeptides.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

1.00 CME / CNE / CPE
Rush University Medical Center
Integrating New Treatment Options for B-Cell Non-Hodgkin Lymphomas into Practice

Integrating New Treatment Options for B-Cell Non-Hodgkin Lymphomas into Practice

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 10, 2020
Expires: December 9, 2021
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.

Learning Objectives

After completing this program, participants should be able to:

  1. Differentiate among emerging and recently approved therapies for B-cell NHLs and review the considerations for their clinical use
  2. Assess the latest clinical data on new and emerging approaches for treating B-cell NHLs in order to best integrate them into care
  3. Formulate individualized, evidence-based best-practice treatment plans for patients with B-cell NHLs

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. This heterogenous group of lymphoproliferative disorders remains a challenge to treat due to differing patterns of behavior and responses to treatment. The ever-changing treatment landscape of NHL provides clinicians new and potentially efficacious approaches with which to treat these challenging cases but selecting a treatment that meets both the clinician’s and the patient’s goals remains challenging. As such, healthcare professionals treating patients with B-cell malignancies will require competency in understanding the application, efficacy, and safety of these new and emerging treatment options to provide sufficient care, support, and treatment.

Faculty

Ian Flinn, MD
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology/OneOncology
Nashville, TN

Conflict of Interest Policy/Disclosure Statement

Dr. Flinn has consulted for:
AbbVie, AstraZeneca, BeiGene, Curio Science, Gilead Science, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincera Pharma, Yingli Pharmaceuticals.

Dr. Flinn has research grants from:
AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, F. Hofman-la Roche Ltd, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm, KITE Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from BMS, Epizyme, Inc. and Janssen Biotech, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 10, 2020
Expires: December 9, 2021
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.

Learning Objectives

After completing this program, participants should be able to:

  1. Differentiate among emerging and recently approved therapies for B-cell NHLs and review the considerations for their clinical use
  2. Assess the latest clinical data on new and emerging approaches for treating B-cell NHLs in order to best integrate them into care
  3. Formulate individualized, evidence-based best-practice treatment plans for patients with B-cell NHLs

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. This heterogenous group of lymphoproliferative disorders remains a challenge to treat due to differing patterns of behavior and responses to treatment. The ever-changing treatment landscape of NHL provides clinicians new and potentially efficacious approaches with which to treat these challenging cases but selecting a treatment that meets both the clinician’s and the patient’s goals remains challenging. As such, healthcare professionals treating patients with B-cell malignancies will require competency in understanding the application, efficacy, and safety of these new and emerging treatment options to provide sufficient care, support, and treatment.

Faculty

Ian Flinn, MD
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology/OneOncology
Nashville, TN

Conflict of Interest Policy/Disclosure Statement

Dr. Flinn has consulted for:
AbbVie, AstraZeneca, BeiGene, Curio Science, Gilead Science, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincera Pharma, Yingli Pharmaceuticals.

Dr. Flinn has research grants from:
AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, F. Hofman-la Roche Ltd, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm, KITE Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by an educational grant from BMS, Epizyme, Inc. and Janssen Biotech, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME
University of Nebraska Medical Center
The Expanding Role of BTK Inhibitors for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

The Expanding Role of BTK Inhibitors for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Start

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: December 7, 2020
Expires: December 7, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Identify the role of BTK signaling in the pathogenesis of CLL, and the rationale for targeting BTK in patients with this malignancy
  • Assess clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
  • Evaluate emerging clinical trial data of current and novel BTK inhibitors, including monotherapy and combination approaches
  • Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as oral adherence strategies

Activity Description

Bruton’s tyrosine kinase (BTK) inhibitors are an evolving therapeutic strategy for the treatment of patients with CLL. With multiple BTK inhibitors (and combinations) under investigation and pending approval, clinicians need expert guidance to correctly use these agents safely and effectively for patients with CLL, and plan strategies for optimal integration of these novel agents into practice. This webcast will provide expert interpretation of emerging data and guidance regarding patient diagnosis, treatment, maintenance therapy, and sequencing of agents.

Statement of Educational Need

BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.

Faculty

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical Center
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research to Practice, TG Therapeutics, Verastem, Inc.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

All disclosed conflicts of interest have been resolved by independent content review.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene and Pharmacyclics.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: December 7, 2020
Expires: December 7, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Identify the role of BTK signaling in the pathogenesis of CLL, and the rationale for targeting BTK in patients with this malignancy
  • Assess clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
  • Evaluate emerging clinical trial data of current and novel BTK inhibitors, including monotherapy and combination approaches
  • Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as oral adherence strategies

Activity Description

Bruton’s tyrosine kinase (BTK) inhibitors are an evolving therapeutic strategy for the treatment of patients with CLL. With multiple BTK inhibitors (and combinations) under investigation and pending approval, clinicians need expert guidance to correctly use these agents safely and effectively for patients with CLL, and plan strategies for optimal integration of these novel agents into practice. This webcast will provide expert interpretation of emerging data and guidance regarding patient diagnosis, treatment, maintenance therapy, and sequencing of agents.

Statement of Educational Need

BTK inhibitors have substantially altered the management, clinical course, and outcome of patients with CLL. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently in clinical development, including acalabrutinib, which is currently US FDA approved for previously treated mantle cell lymphoma. Significant efforts are underway to investigate the optimal combinations, timing, and sequencing of BTK inhibitors with other regimens and targeted agents, and to capitalize on the immunomodulatory modes of action of BTK inhibitors to correct tumor-induced immune defects and to achieve long-lasting tumor control.

Faculty

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical Center
Associate Director, Center for Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts

Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research to Practice, TG Therapeutics, Verastem, Inc.

Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

All disclosed conflicts of interest have been resolved by independent content review.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene and Pharmacyclics.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

info@bioascend.com

1.00
AcademicCME
Diagnosis and Management of Acquired Methemoglobinemia

Diagnosis and Management of Acquired Methemoglobinemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Emergency medicine physicians, intensivists, toxicologists, infectious disease specialists, oncologists, advanced practitioners, nurses, hospital-based pharmacists, and other healthcare professionals involved in the care of patients with acquired methemoglobinemia.

Learning Objectives

  1. Discuss the pathophysiologic basis of methemoglobinemia, explain the origin of the “saturation gap,” and apply that to diagnostic evaluation
  2. Analyze available data on the various treatment options for acquired methemoglobinemia
  3. Develop therapeutic plans and monitor adverse side effects with the multidisciplinary care team to improve patient outcomes

Activity Description

The diagnosis of acquired methemoglobinemia requires a high index of clinical suspicion, confirmation with objective testing, and prompt specific treatment in addition to support. There are important clues to the diagnosis, especially a “saturation gap” between an arterial blood gas and pulse oximetry data, and careful history of drug use or potential toxin exposure. Because acquired methemoglobinemia is rare, clinicians should seek out and pursue education on the most up-to-date information on etiology, diagnosis, and treatment.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with acquired methemoglobinemia.

Agenda

  1. Patient Case 1 Analysis: An Ill Patient with an Oxygen Saturation Gap
  2. Pathophysiology of Acquired Methemoglobinemia: Identifying the Usual Suspects, but in Context
  3. Clinical Strategies to Improve Outcomes in Patients with Acquired Methemoglobinemia
  4. Patient Case 2 Analysis: Acute Decompensation in the ICU
  5. An Interprofessional Approach to Treatment Plan Development & Patient Monitoring

Faculty

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


John Fanikos, RPh, MBA
Executive Director of Pharmacy
Brigham and Women’s Hospital
Boston, Massachusetts


Frank LoVecchio, DO, MPH, FACEP, ABMT
Professor, Research Scholar, University of Arizona
Emergency Medicine, Medicine and Pharmacology
Tucson, Arizona


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)

Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.

Consultant/Advisor: AstraZeneca Pharmaceuticals

John Fanikos, RPh, MBA

Consultant/Advisor: AstraZeneca Pharmaceuticals; Boehringer Ingelheim International GmbH; Portola Therapeutics, Inc.; Ipsen Pharmaceuticals, Inc.

Grant/Research Support: Boehringer Ingelheim International GmbH; Heron Therapeutics, Inc.

Frank LoVecchio, DO, MPH, FACEP, ABMT

Grant/Research Support: National Institutes of Health

Speaker’s Bureau: Allergan

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hours, including 1.0 Pharmacotherapeutic Contact Hours (Provider number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hours (0.10 CEUs) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-012-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from PROVEPHARM INC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PROVEPHARM INC. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Emergency medicine physicians, intensivists, toxicologists, infectious disease specialists, oncologists, advanced practitioners, nurses, hospital-based pharmacists, and other healthcare professionals involved in the care of patients with acquired methemoglobinemia.

Learning Objectives

  1. Discuss the pathophysiologic basis of methemoglobinemia, explain the origin of the “saturation gap,” and apply that to diagnostic evaluation
  2. Analyze available data on the various treatment options for acquired methemoglobinemia
  3. Develop therapeutic plans and monitor adverse side effects with the multidisciplinary care team to improve patient outcomes

Activity Description

The diagnosis of acquired methemoglobinemia requires a high index of clinical suspicion, confirmation with objective testing, and prompt specific treatment in addition to support. There are important clues to the diagnosis, especially a “saturation gap” between an arterial blood gas and pulse oximetry data, and careful history of drug use or potential toxin exposure. Because acquired methemoglobinemia is rare, clinicians should seek out and pursue education on the most up-to-date information on etiology, diagnosis, and treatment.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with acquired methemoglobinemia.

Agenda

  1. Patient Case 1 Analysis: An Ill Patient with an Oxygen Saturation Gap
  2. Pathophysiology of Acquired Methemoglobinemia: Identifying the Usual Suspects, but in Context
  3. Clinical Strategies to Improve Outcomes in Patients with Acquired Methemoglobinemia
  4. Patient Case 2 Analysis: Acute Decompensation in the ICU
  5. An Interprofessional Approach to Treatment Plan Development & Patient Monitoring

Faculty

Charles V. Pollack Jr., MA, MD
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


John Fanikos, RPh, MBA
Executive Director of Pharmacy
Brigham and Women’s Hospital
Boston, Massachusetts


Frank LoVecchio, DO, MPH, FACEP, ABMT
Professor, Research Scholar, University of Arizona
Emergency Medicine, Medicine and Pharmacology
Tucson, Arizona


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack Jr., MA, MD (Course Chair)

Grant/Research Support: AstraZeneca Pharmaceuticals; PROVEPHARM INC.

Consultant/Advisor: AstraZeneca Pharmaceuticals

John Fanikos, RPh, MBA

Consultant/Advisor: AstraZeneca Pharmaceuticals; Boehringer Ingelheim International GmbH; Portola Therapeutics, Inc.; Ipsen Pharmaceuticals, Inc.

Grant/Research Support: Boehringer Ingelheim International GmbH; Heron Therapeutics, Inc.

Frank LoVecchio, DO, MPH, FACEP, ABMT

Grant/Research Support: National Institutes of Health

Speaker’s Bureau: Allergan

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hours, including 1.0 Pharmacotherapeutic Contact Hours (Provider number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hours (0.10 CEUs) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-012-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from PROVEPHARM INC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and PROVEPHARM INC. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Pages